January 2026 marked a significant month for FDA drug approvals, label updates, and public health policy changes. From breakthrough oncology combinations and first in class treatments for rare pediatric diseases to updates in diabetes management, contraception, ophthalmology, and vaccine policy, these developments reflect evolving clinical evidence and patient needs across multiple specialties.
This comprehensive roundup highlights the most important FDA decisions from January 2026 and explains what they mean for clinicians, patients, caregivers, and the healthcare system at large.
The FDA approved Darzalex Faspro in combination with bortezomib, lenalidomide, and dexamethasone for adults with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant.
Multiple myeloma is a cancer of plasma cells in the bone marrow and is associated with bone pain, anemia, kidney dysfunction, and fractures. While treatment options have expanded over the past decade, outcomes remain poorer for patients who cannot undergo transplant.
Approval was based on results from the Phase 3 CEPHEUS trial, which enrolled 395 patients who were transplant ineligible or deferred transplant. The primary endpoint was minimal residual disease negativity, a sensitive measure of deep treatment response.
At a median follow up of 22 months, more than half of patients receiving the Darzalex Faspro based regimen achieved MRD negativity at a sensitivity of 10 to the minus 5 level. This compared with just over one third of patients receiving standard therapy alone.
Longer follow up demonstrated sustained MRD negativity, higher complete response rates, and a 40 percent reduction in the risk of disease progression or death.
Darzalex Faspro is administered as a short subcutaneous injection over three to five minutes, rather than hours of intravenous infusion. This significantly reduces chair time, improves patient convenience, and lowers infusion related reactions.
Common side effects include infections, neuropathy, fatigue, diarrhea, edema, and respiratory symptoms. Clinicians must also be aware of risks such as neutropenia, thrombocytopenia, embryo fetal toxicity, and interference with blood compatibility testing.
The FDA approved Yuvezzi, a fixed dose combination of carbachol and brimonidine tartrate, for the treatment of presbyopia in adults. Presbyopia affects nearly everyone over age 45 and results in progressive difficulty with near vision.
Yuvezzi is the first eye drop to combine two active agents designed to enhance pupil constriction and depth of focus.
Carbachol induces miosis by stimulating cholinergic receptors. Brimonidine enhances and prolongs this effect through alpha 2 adrenergic activity. Together, they create a pinhole effect that improves near vision without significant loss of distance vision.
The effects begin within 30 minutes and can last up to 10 hours with once daily dosing.
In the Phase 3 BRIO studies, patients aged 45 to 80 achieved statistically significant improvements in binocular uncorrected near visual acuity without clinically meaningful reductions in distance vision. Vision improvements were maintained for up to eight hours.
The most common adverse effects include temporary eye irritation, headache, and blurred vision. Patients should be cautioned about driving or operating machinery if vision is impaired, particularly in low light conditions.
Yuvezzi is expected to be available in the United States in the second quarter of 2026.
One of the most impactful approvals in January 2026 was Zycubo, the first FDA approved treatment for Menkes disease. This rare X linked genetic disorder impairs copper transport, leading to severe neurodegeneration and early death if untreated.
Zycubo contains copper histidinate formulated for subcutaneous injection at physiological pH. By bypassing defective intestinal absorption, it delivers bioavailable copper directly into the bloodstream.
Clinical trials demonstrated dramatic survival improvements, particularly when treatment began within four weeks of birth. Nearly half of early treated children survived beyond six years, compared with no survivors in untreated controls.
Even children treated later showed significant survival benefits, extending median survival from less than two years to more than five years.
Because copper accumulation can be toxic, careful monitoring of copper levels, liver function, kidney function, and blood counts is required. Common adverse effects include infections, seizures, anemia, and injection site reactions.
The FDA approved an extended duration of use for the Nexplanon birth control implant, increasing approved use from three to five years.
Nexplanon is a subdermal implant containing the progestin etonogestrel and is one of the most effective forms of reversible contraception.
In a multicenter study of 399 women, no pregnancies were reported during years four and five of use. Importantly, the study included women across a wide range of body mass index values, including those with obesity.
No new safety concerns were identified during extended use.
Nexplanon carries a boxed warning related to insertion and removal complications. Other risks include changes in menstrual bleeding, ectopic pregnancy, thrombotic events, and blood pressure elevation.
The product remains available only through a restricted training and certification program.
The FDA cleared updated prescribing information for Afrezza, an inhaled rapid acting insulin for adults with diabetes.
Afrezza offers needle free mealtime insulin delivery and begins lowering blood glucose levels within minutes.
The revised label includes clearer dose conversion tables for patients switching from injectable or pump based mealtime insulin. This helps clinicians initiate therapy more safely and consistently.
The update was supported by modeling data and clinical trial results showing improved post meal glucose control using the new dosing guidance.
Afrezza is not appropriate for patients with asthma, COPD, or other chronic lung disease. Baseline and periodic lung function testing remains mandatory. Common side effects include hypoglycemia, cough, and throat irritation.
The FDA announced plans to remove suicidal behavior and ideation warnings from labeling for GLP 1 receptor agonists approved for chronic weight management.
Affected medications include liraglutide, semaglutide, and tirzepatide.
A large meta analysis of more than 90 randomized controlled trials involving over 100000 patients found no increased risk of suicidality or psychiatric adverse events compared with placebo.
Real world data from FDA Sentinel analyses involving more than two million patients also showed no increased risk of intentional self harm.
The original warnings were based on older weight loss medications rather than evidence from GLP 1 therapies themselves.
This decision may reduce stigma and hesitation around prescribing these effective obesity treatments.
Accord BioPharma received FDA clearance for Filkri, a biosimilar to Neupogen. Filgrastim products stimulate white blood cell production and are used to prevent infections in patients undergoing chemotherapy or stem cell transplantation.
Filkri demonstrated no clinically meaningful differences in safety, purity, or potency compared with the reference product. It is available in prefilled syringes for intravenous or subcutaneous administration.
Risks include spleen rupture, acute respiratory distress syndrome, serious allergic reactions, sickle cell crises, and hematologic abnormalities. Bone pain and fever remain common side effects.
A controversial CDC decision to narrow routine childhood vaccine recommendations sparked concern across the medical community in January 2026.
The updated CDC schedule reduced routine vaccination coverage from 17 diseases to 11, shifting several vaccines to shared clinical decision making rather than universal recommendation.
The American Academy of Pediatrics reaffirmed its full evidence based schedule, supported by major medical organizations including the American Medical Association.
Many pediatricians report continuing to follow the AAP schedule, citing strong safety and effectiveness data and concerns about declining vaccination rates.
The Department of Health and Human Services confirmed that vaccines recommended by the CDC as of December 31 2025 will continue to be covered by insurance plans under the Affordable Care Act.
The FDA actions in January 2026 reflect both scientific progress and ongoing debates in public health policy. Breakthrough approvals like Zycubo and expanded indications for Darzalex Faspro offer meaningful benefits for patients with serious and rare diseases. Meanwhile, updates to contraception, diabetes care, and obesity treatment improve access and clarity for millions of Americans.
As healthcare continues to evolve, staying informed about regulatory changes is essential for clinicians, patients, and policymakers alike. January 2026 set the tone for a year focused on precision medicine, patient convenience, and evidence driven decision making.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.